Skip to main content

Publications

featured publications

  • High Prevalence of F2 20210G > A in Splanchnic Vein Thrombosis and Cerebral Venous Sinus Thrombosis: A Retrospective Cohort Study of Patients with Thrombosis in Atypical Sites.

    Hamostaseologie

    Authors: Dalia Khaddam, Hannah L McRae, Nadine Schwarz, Johannes Oldenburg, Bernd Pötzsch, Heiko Rühl, Sara Reda

  • Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A.

    Journal of thrombosis and haemostasis : JTH

    Authors: Christina Hart, Robert Klamroth, Ulrich J Sachs, Richard Greil, Paul Knoebl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Isabell Pekrul, Katharina Holstein, Hermann Eichler, Carmen Weigt, Dorothea Schipp, Sonja Werwitzke, Andreas Tiede

  • Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany.

    Research and practice in thrombosis and haemostasis

    Authors: Christoph Bidlingmaier, Christine Heller, Florian Langer, Wolfgang Miesbach, Ute Scholz, Johannes Oldenburg, Eveline Nüesch, Helena Palmborg, Elena Santagostino, Andreas Tiede

  • Self-conducted sonographic monitoring of the knee in patients with haemophilia-A feasibility study.

    Haemophilia : the official journal of the World Federation of Hemophilia

    Authors: Anna Christina Strauss, Natascha Marquardt, Johannes Oldenburg, Claus Christian Pieper, Ulrike Attenberger, Jamil Hmida, Charlotte Rommelspacher, Sebastian Koob, Andreas Christian Strauss

  • Quantitative analysis of heme and hemoglobin for the detection of intravascular hemolysis.

    Analytica chimica acta

    Authors: Marie-T Hopp, Sonali M Vaidya, Karina M Grimmig, Lasse J Strudthoff, Johanna C Clauser, Xiaojing Yuan, Sneha Singh, Jens Müller, Johannes Oldenburg, Iqbal Hamza, Diana Imhof

  • Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review.

    Research and practice in thrombosis and haemostasis

    Authors: Guy Young, Steven W Pipe, Gili Kenet, Johannes Oldenburg, Mariam Safavi, Tuende Czirok, Francis Nissen, Johnny Mahlangu

  • Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.

    Advances in therapy

    Authors: Johannes Oldenburg, Herve Chambost, Hai Liu, Charles Hawes, Xiaojun You, Xinqun Yang, Vanessa Newman, Tara M Robinson, Anthony J Hatswell, David Hinds, Sandra Santos, Margareth Ozelo

  • In-depth structure-function profiling of the complex formation between clotting factor VIII and heme.

    Thrombosis research

    Authors: Marie-T Hopp, Deniz Ugurlar, Behnaz Pezeshkpoor, Arijit Biswas, Anuradha Ramoji, Ute Neugebauer, Johannes Oldenburg, Diana Imhof

  • Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.

    Journal of thrombosis and haemostasis : JTH

    Authors: Bella Madan, Margareth C Ozelo, Priyanka Raheja, Emily Symington, Doris V Quon, Andrew D Leavitt, Steven W Pipe, Gillian Lowe, Gili Kenet, Mark T Reding, Jane Mason, Michael Wang, Annette von Drygalski, Robert Klamroth, Susan Shapiro, Hervé Chambost, Amy L Dunn, Johannes Oldenburg, Sheng-Chieh Chou, Flora Peyvandi, Carolyn M Millar, Dane Osmond, Hua Yu, Ebony Dashiell-Aje, Tara M Robinson, Johnny Mahlangu

  • Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.

    Research and practice in thrombosis and haemostasis

    Authors: Víctor Jiménez-Yuste, Johannes Oldenburg, Eunice Tzeng, Elise Lim, Fabian Sanabria, Johnny Mahlangu